What Lysobact Complete Treats: Main Uses and Benefits

Lysobact Complete is commonly used to offer symptomatic relief for symptoms associated with acute conditions of the mouth and throat. This medication is applied in clinical settings that involve acute or unstable symptom patterns, consistent with its therapeutic properties.

It is generally relevant for easing symptoms related to inflammatory or irritative states, which may include soreness, swelling, difficulty swallowing, and minor oral lesions. The product is applicable in conditions characterized by periods of heightened symptoms, which may include a sore throat, inflammation of the gums (gingivitis), or small mouth ulcers.

This approach supports the patient during difficult episodes by easing distress from symptoms related to physical discomfort. This contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Support for Symptoms Related to Physical Discomfort

The product is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. Philippine Food and Drug Administration's (FDA) Lysobact Spray Document

Who can and cannot use Lysobact Complete

Official regulatory documents strictly define the patient population eligible to use Lysobact Complete, primarily based on contraindications related to hypersensitivity and age.

---

Contraindicated Populations

Use of this medicine is absolutely prohibited (contraindicated) in the following groups:

• Patients with documented hypersensitivity to any of the active substances (Lidocaine, Cetylpyridinium, Lysozyme).
• Individuals with known allergy to egg white (due to the Lysozyme component) or to other amide-type local anesthetics.
• Children below 6 years of age. Some regulatory documents apply a stricter contraindication for children under 30 months of age.

---

Restricted or Conditional Use

Regulatory guidance specifies that Lysobact Complete is not recommended for use during pregnancy or while breastfeeding (lactation). Furthermore, special consideration or caution is required for patients with large or fresh wounds in the mouth or pharynx, due to the potential for systemic absorption of the active ingredients. The product is generally intended for use by adults and children over 6 years of age.

Documented Interactions and Required Restrictions

This section details the officially documented interaction information for Lysobact Complete (containing Lidocaine, Cetylpyridinium, and Lysozyme) based strictly on authoritative government regulatory sources.

Interaction Type	Interacting Product Category	Regulatory Requirement
Pharmacodynamic Restriction	Other Local Antiseptics	Must not be simultaneously taken for the purpose of disinfecting the mouth and/or throat.
Pharmacokinetic Caution	Medicines for Epilepsy (e.g., Phenytoin, Barbiturates)	Requires special caution when co-administered.

---

Timing-Based and Population-Specific Constraints

Official regulatory documents establish constraints related to the ingestion of products and specific patient populations due to the presence of the anesthetic component.

• Food and Drinks: A timing-based restriction is mandated: patients must not take any food or drinks for one hour after using the spray. This is related to the local anesthetic effect.
• Porphyria Caution: The regulatory labeling notes a population-specific consideration for patients with Porphyria (a rare blood pigment disorder). Use is restricted to vital and urgent conditions only, and special precaution must be exercised.

These official statements define the product's interaction profile by setting clear rules for co-administration, requiring caution with specific drug classes, and establishing time separation from oral intake.

Lysobact Complete delivers three active components to the oral and pharyngeal mucosa: lysozyme, cetylpyridine chloride, and lidocaine hydrochloride. Lysozyme is an enzyme that catalyzes the hydrolysis of N-acetylmuramide-beta-(1 ightarrow 4)-N-acetylglucosamine linkages, specifically targeting the beta-(1 ightarrow 4) glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine within the peptidoglycan layer of bacterial cell walls

. This lytic activity compromises bacterial cell envelope integrity, leading to osmotic instability. Lysozyme also mediates immunomodulatory effects by stimulating local immune cells and stabilizing the membranes of cells involved in inflammatory signaling, thereby reducing the localized generation of inflammatory mediators. Cetylpyridine chloride is a quaternary ammonium compound that functions as a broad-spectrum antiseptic. Its cationic structure interacts with the negatively charged components of microbial cell membranes, increasing cell membrane permeability and causing leakage of intracellular contents. Lidocaine hydrochloride is a local anesthetic that acts as a voltage-gated sodium channel blocker. By binding to the intracellular domain of the channel, it prevents the influx of sodium ions required for the generation and propagation of action potentials in sensory nerve endings localized in the mucosal tissue, resulting in attenuated neural transmission of local stimuli.

How to Use Lysobact Complete: Administration Guidelines

Lysobact Complete is a multicomponent oropharyngeal preparation for local, short-term use, with a strictly defined administration pattern.

---

Administration Scope

Feature	Guideline Details
Route of administration	The product is administered via the oromucosal route, meaning it is applied directly to the mucous membranes of the mouth and throat.
Dosing schedule	The standard single dose is 5 spray pump presses, which delivers 1.0 mL of solution. This 1.0 mL contains 20 mg Lysozyme, 1.5 mg Cetylpyridinium, and 0.5 mg Lidocaine.
Frequency and timing	Use is authorized for 3 to 6 times per day. A mandatory minimum interval of 2 hours must be maintained between doses.
Age-group rules	The preparation is not recommended for use in children aged below 6 years.
Course duration	The duration of treatment is restricted to a maximum of 5 days.

---

Procedural Administration and Timing

Use of the oromucosal spray requires specific actions to ensure proper application. During administration, the user is instructed to hold their breath to prevent inhalation. The medicine is not to be swallowed, reinforcing its designation as a strictly local treatment. For hygienic purposes, the product should be used by only one patient.

In the event a dose is forgotten, the guideline is to not use a double dose to compensate. The user should apply the missed dose as soon as it is remembered and then resume the standard scheduled application intervals. The solution is sugar-free and may be used by individuals with diabetes.

Research Evidence / Overview of Studies for Lysobact Complete

---

Research Evidence for Symptomatic Relief in Acute Sore Throat

Research exploring the combination product was used in studies examining outcomes related to physical discomfort during acute sore throat. The evidence base includes Randomized Controlled Trials (RCTs) and controlled comparative studies. These studies were applied in research contexts involving fluctuating or unstable symptoms, and were used to examine how symptoms are measured over defined time intervals.

In these trials, researchers primarily monitored patient-reported outcomes describing perceived discomfort in the throat. The outcomes related to physical discomfort that were studied include pain intensity and scores related to the difficulty of swallowing. Research highlights changes measured during the study period, and these findings describe group patterns, not personal outcomes, as study results reflect the specific conditions under which they were conducted.

---

Research Evidence in Observational Settings for Oral Mucositis

Research also studies explored the use of the enzyme component (Lysozyme) in observational settings evaluating specific types of inflammation, such as oral mucositis. The evidence here is generally derived from observational settings evaluating daily-life functioning and smaller comparative studies, with fewer large-scale RCTs available in this specific context.

In these studies, the research examined outcomes reflecting daily functioning or activity level, such as pain intensity during functional activities like eating and speaking. This research contributes to the broader evidence landscape regarding the product's use for conditions involving periods of heightened symptoms in the mouth.

---

Understanding Study Duration and Long-Term Follow-up

The available research primarily focuses on short-term symptom changes. Studies exploring immediate symptomatic patterns typically evaluate changes over a matter of hours following a single administration. For this type of local symptomatic treatment, follow-up durations were limited. Evidence is limited regarding the long-term effects on disease progression, recurrence rates, or the durability of symptomatic patterns beyond the acute episodes studied.

---

Evidence in Specific Patient Populations

The majority of the available, controlled clinical data for the product's primary use in sore throat was evaluated in adult populations (18 years and older). This means that the results apply only to the populations studied in those controlled settings. Data for certain groups remain insufficient. For instance, there is limited information for specific subgroups, such as pediatric patients (children and adolescents). Similarly, research exploring the product in populations with multiple comorbid conditions or in specific vulnerable groups is sparse or not available in the core evidence summaries.

---

Areas of Uncertainty and Research Gaps

The research base for this combination, while including RCTs for symptomatic patterns, still has identifiable gaps in the evidence. One limitation is that the sample sizes were modest in some of the pivotal trials. Furthermore, the evidence quality varies across studies, particularly when moving from the primary indication to supportive uses, where the evidence relies more heavily on observational reports. The research highlights what is known — and what is still uncertain — regarding the product's use outside of the specific, short-term circumstances under which the studies were conducted.

Key Studies & References

1. Lysozyme, NCBI Bookshelf (Molecular Mechanisms of Defense)
2. Lysobact Spray Document (Philippine Food and Drug Administration Regulatory Document)

Common questions about Lysobact Complete (FAQ)

---

Q: Does this medication make you tired or sleepy?

Official regulatory documents list potential side effects affecting the central nervous system, such as somnolence (drowsiness) or fatigue. Patients should be aware of potential effects on tasks requiring mental alertness, such as driving or operating machinery, if they experience these effects.

---

Q: Can I still drink alcohol while taking this?

Official product labeling specifies whether the use of alcohol should be avoided while taking this medication. This is usually due to the potential for an interaction that could result in enhanced effects of the medication or of the alcohol itself. Patients are referred to the official product information for specific statements regarding concurrent alcohol consumption.

---

Q: Is it safe to use during pregnancy?

Regulatory documents contain a statement regarding the use of this medication during pregnancy. This information summarizes the available data on risks and benefits and outlines the drug's established risk/benefit profile for use in this specific population.

---

Q: What happens if I miss a dose?

Official labeling contains specific instructions on what course of action to take if a dose is missed. These directions are found within the 'How to use' or 'Posology' section of the product information and should be consulted.

---

Q: Can a 2-year-old child use this?

Official regulatory documents explicitly state the approved age groups for which the medication has been tested and authorized. If the 2-year-old age group is not listed within the approved therapeutic indications and dosing sections, the product is not approved for use in that age range. Use of the product is restricted to the specific populations that are explicitly listed on the label.

---

Q: Will this medication interact with my blood pressure pills?

The official product information addresses potential drug-drug interactions. These interactions are often categorized by the type of medication, such as 'Antihypertensives' (blood pressure-lowering drugs). Regulatory documents list which specific combinations should be avoided or used with caution.

How to Store and Dispose of Lysobact Complete?

Strict adherence to official labeled instructions is required to maintain the stability and safety of Lysobact Complete Spray.

Storage Requirement	Official Regulatory Statement
Temperature	Do not store above 25°C.
Freezing	Do not freeze.
Child Safety	Keep out of the reach and sight of children.
Expiration	Do not use after the expiry date stated on the pack.

This medicine has an officially documented shelf life of 24 months from the date of manufacture. The required storage profile—mandating storage below 25°C and prohibiting freezing—ensures the product's quality. Disposal instructions strictly prohibit use beyond the documented expiration date, reinforcing stability and safety standards.